Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Quotient Sciences Expands Formulation Development Capabilities | Contract Pharma

What are you searching for?

Sign in
Breaking News

Quotient Sciences Expands Formulation Development Capabilities

The expansion builds upon existing capabilities and increases capacity to support fully integrated drug development programs.

By: Anthony Vecchione

Quotient Sciences, the drug development and manufacturing accelerator, has completed an expansion of its early-phase formulation development capabilities for oral dosage forms at its Nottingham, UK, facility.

The expanded services build upon the site’s existing formulation capabilities and increases capacity to support fully integrated drug development programs through the company’s flagship platform, Translational Pharmaceuticals.

With this latest investment, the company has expanded its high containment laboratory capacity to support oral drug programs including immediate release, modified release tablet and multi-particulate dosage forms for highly potent compounds.

“At Quotient Sciences, our expertise in formulation development is underpinned by our unique track record in clinical research. Having both biopharmaceutics and clinical knowledge in-house, coupled with our experience from formulating over 1,500 molecules, enables us to accelerate the development process for our customers,” said Andy Lewis, global vice president of integrated pharmaceutical sciences at Quotient Sciences.

Lewis added, “With these expanded capabilities, we can start formulation development work even earlier for our customers, allowing for projects to start faster and turnaround times to be reduced, which in turn will speed up development timelines. Importantly, the new equipment and process trains are fully integrated with our existing capabilities, so at the appropriate point we can quickly transition drug programs downstream into GMP clinical trial manufacturing, saving our customers precious time in advancing innovative medicines into the clinic.”

Mark Egerton, CEO of Quotient Sciences, said, “Quotient Sciences’ mission is to help get new medicines to patients faster and over the course of the last decade we’ve been investing in capabilities to support that. We place a great importance on supporting customer demand and will continue to actively increase our formulation tool kit to provide more integrated solutions under a single organization to streamline the outsourcing paradigm for our customers.”

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics